Skip to main content

Advertisement

SpringerLink
Log in

Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?

  • Translational Colorectal Oncology (Y Jiang, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Despite adjuvant chemotherapy, between 20 and 50 % of patients with stage II/III colorectal cancer (CRC) will suffer recurrence, usually as incurable metastatic disease. Attempts to improve the efficacy of adjuvant regimens with addition of biologics have failed, and there is therefore a pressing need for novel therapeutic approaches. Inflammatory mediators, including the cyclooxygenase (COX) enzyme family, are commonly upregulated in CRC and known to promote tumour growth in preclinical models. COX inhibition by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may exert an antineoplastic effect. Despite considerable evidence in CRC prevention and emerging data demonstrating that regular aspirin reduces the frequency of metastases following CRC resection, its use has not become widespread due to concerns regarding toxicities. However, the recent identification of biomarkers that may predict aspirin benefit has renewed interest in the field. Large, randomised controlled trials underway/in set-up should provide definitive evidence of the efficacy of aspirin/NSAIDs as adjuvant therapy in CRC. This review examines the field to date, with focus on the biomarkers which may help refine the risk-benefit ratio.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  PubMed  CAS  Google Scholar 

  2. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.

    Article  PubMed  Google Scholar 

  3. Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    Article  Google Scholar 

  4. Ali R, Toh HC, Chia WK. The utility of aspirin in dukes C and high risk dukes B colorectal cancer—the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011;12:261. Trial protocol for ongoing multicentre randomised controlled trial of low-dose (200 mg) aspirin vs. placebo in adjuvant treatment of CRC.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    Article  PubMed  CAS  Google Scholar 

  6. Twelves C, Wong A, Nowacki MP, Abt M, Burris 3rd H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.

    Article  PubMed  CAS  Google Scholar 

  7. Park JH, McMillan DC, Horgan PG, Roxburgh CS. The impact of anti-inflammatory agents on the outcome of patients with colorectal cancer. Cancer Treat Rev. 2014;40(1):68–77.

    Article  PubMed  CAS  Google Scholar 

  8. Crawford S. Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. Ther Adv Med Oncol. 2014;6(2):52–68.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518–27. Systematic summary of data regarding aspirin effect on CRC outcomes from randomised and observational studies.

    Article  PubMed  CAS  Google Scholar 

  10. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–9.

    Article  PubMed  CAS  Google Scholar 

  11. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5(2):164–78.

    Article  CAS  Google Scholar 

  13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.

    Article  PubMed  CAS  Google Scholar 

  14. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379(9826):1602–12.

    Article  PubMed  CAS  Google Scholar 

  15. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.

    Article  PubMed  CAS  Google Scholar 

  16. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.

    Article  PubMed  CAS  Google Scholar 

  17. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKB, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Schrör K. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol. 2011;25(4):473–84.

    Article  PubMed  Google Scholar 

  19. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.

    Article  PubMed  CAS  Google Scholar 

  20. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW. Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res. 2011;4(1):161–71.

    Article  CAS  Google Scholar 

  21. Gao F, Liao C, Liu L, Tan A, Cao Y, Mo Z. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Color Dis. 2009;11(9):893–901.

    Article  CAS  Google Scholar 

  22. Boon EMJ, Keller JJ, Wormhoudt TAM, Giardiello FM, Offerhaus GJA, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90(1):224–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Burn J, Bishop DT, Mecklin JP, Macrae F, Moslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008;359(24):2567–78.

    Article  PubMed  CAS  Google Scholar 

  24. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313–6.

    Article  PubMed  CAS  Google Scholar 

  25. Neugut AI. Aspirin as adjuvant therapy for stage III colon cancer: standard of care? JAMA Intern Med. 2014;174(5):739–41.

    Article  PubMed  Google Scholar 

  26. Baron JA. Aspirin and cancer: trials and observational studies. J Natl Cancer Inst. 2012;104(16):1199–200.

    Article  PubMed  CAS  Google Scholar 

  27. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106(9):1564–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, et al. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case-control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700–708.e2.

    Article  PubMed  CAS  Google Scholar 

  29. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649–58.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9(10):561–70.

    Article  PubMed  CAS  Google Scholar 

  31. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut. 2011;60(4):491–8.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Fuchs CS, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from intergroup trial CALGB 89803. J Clin Oncol (Meeting Abstracts). 2005;23(16):Suppl 3530.

    Google Scholar 

  33. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer. 2013;109(7):1921–5.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  34. McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer. 2013;49(5):1049–57.

    Article  PubMed  CAS  Google Scholar 

  35. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59(12):1670–9.

    Article  PubMed  CAS  Google Scholar 

  36. Reimers MS, Bastiaannet E, van Herk-Sukel MP, Lemmens VE, van den Broek CB, van de Velde CJ, et al. Aspirin use after diagnosis improves survival in older adults with colon cancer: a retrospective cohort study. J Am Geriatr Soc. 2012;60(12):2232–6.

    Article  PubMed  Google Scholar 

  37. Walker AJ, Grainge MJ, Card TR. Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 2012;107(9):1602–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  38. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer. 2009;115(24):5662–71.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Langley RE, Rothwell PM. Aspirin in gastrointestinal oncology: new data on an old friend. Curr Opin Oncol. 2014;26(4):441–7. Summary of evidence leading to the Add-Aspirin trial with description of trial protocol of aspirin at 100 or 300 mg vs. placebo in adjuvant treatment of CRC.

    Article  PubMed  CAS  Google Scholar 

  40. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33:2949–55.

    Article  PubMed  CAS  Google Scholar 

  41. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.

    Article  CAS  Google Scholar 

  42. Langley RE, Rothwell PM. Biological markers: potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol. 2013;10(1):8–10.

    Article  PubMed  CAS  Google Scholar 

  43. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606. Observational data demonstrating reduction in cancer-specific death associated with low-dose aspirin use post diagnosis, restricted to those participants with PIK3CA mutation.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24):2563–71.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  45. Pendlebury S, Duchesne F, Reed KA, Smith JL, Kerr DJ. A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer. 2003;3(1):58–60.

    Article  PubMed  Google Scholar 

  46. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–305. Molecular analysis of cohort of patients from the VICTOR trial demonstrating correlation between PIK3CA mutation and improved survival with aspirin use after CRC diagnosis.

    Article  PubMed  CAS  Google Scholar 

  47. Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol/Hematol. 2004;52(2):81–101.

    Article  CAS  Google Scholar 

  48. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736–47.

    Article  PubMed  Google Scholar 

  49. Bruno A, Dovizio M, Tacconelli S, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2012;26(4):e1–e13.

    Article  PubMed  CAS  Google Scholar 

  50. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(5):447–53.

    PubMed  CAS  Google Scholar 

  51. Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002;11(3):275–9.

    PubMed  CAS  Google Scholar 

  52. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014;174(5):732–9. Observational study demonstrating improved survival in participants using aspirin post-diagnosis with HLA class 1 antigen expression vs those missing HLA-1 expression. Does not show greater benefit of aspirin with PIK3CA mutation demonstrated by Domingo et al. and Liao et al.

    Article  PubMed  CAS  Google Scholar 

  53. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307–14.

    Article  PubMed  CAS  Google Scholar 

  54. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med. 2007;357(4):360–9.

    Article  PubMed  CAS  Google Scholar 

  55. Sheehan KM, Sheahan K, O’Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282(13):1254–7.

    Article  PubMed  CAS  Google Scholar 

  56. Al-Maghrabi J, Buhmeida A, Emam E, Syrjanen K, Sibiany A, Al-Qahtani M, et al. Cyclooxygenase-2 expression as a predictor of outcome in colorectal carcinoma. World J Gastroenterol. 2012;18(15):1793–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  57. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol. 2010;28(30):4575–80.

    Article  PubMed  CAS  Google Scholar 

  58. Auman JT, Church R, Lee S-Y, Watson MA, Fleshman JW, McLeod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer. 2008;44(12):1754–60.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  59. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–42.

    Article  PubMed  CAS  Google Scholar 

  60. Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, et al. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012;32(8):3559–63.

    PubMed  CAS  PubMed Central  Google Scholar 

  61. National Cancer Institute: Oxaliplatin, leucovorin calcium, and fluorouracil with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. NCT01150045. http://clinicaltrials.gov/ct2/show/record/NCT01150045; 2013.

  62. Fuchs CS, Ogino S. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex! J Clin Oncol. 2013;31(34):4358–61.

    Article  PubMed  CAS  Google Scholar 

  63. Cathomas G. PIK3CA in colorectal cancer. Front Oncol. 2014;4:35.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, et al. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell Oncol (Dordr). 2011;34(6):523–31.

    Article  Google Scholar 

  65. Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–8.

    Article  PubMed  CAS  Google Scholar 

  66. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576–90.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  67. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6(233):233re2.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014;106(4):dju016.

    Article  PubMed  Google Scholar 

  69. Nan H, Morikawa T, Suuriniemi M, Imamura Y, Werner L, Kuchiba A, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105(24):1852–61.

    Article  PubMed  CAS  Google Scholar 

  70. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A. 2009;106(23):9409–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  71. Evidence for the use of aspirin as a treatment for cancer and the planned Add-Aspirin trial. http://www.comtecmed.com/cigi/2013/Abstracts_Text.aspx.

  72. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8(2):e57578.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Katie Herbert declares that she has no conflict of interest. Rachel Kerr declares that she has no conflict of interest. David J. Kerr has received an unrestricted study grant supporting the VICTOR trial and has served as a consultant for Bayer. David N. Church declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Oncology, University of Oxford, Oxford, UK

    Katie Herbert, Rachel Kerr, David J. Kerr & David N. Church

  2. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

    David J. Kerr

  3. The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK

    David N. Church

Authors
  1. Katie Herbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David N. Church
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David N. Church.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herbert, K., Kerr, R., Kerr, D.J. et al. Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?. Curr Colorectal Cancer Rep 10, 363–371 (2014). https://doi.org/10.1007/s11888-014-0247-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-014-0247-0

Keywords

Search

Navigation